FINNENCE ▪ THE WIRE FILE
THE WIRE · № 67073
News■ Unclear/unknown
DarioHealth Announces Independent Aon Analysis that Supports Estimated 2.5%-7.2% In-Year Reduction in Total Healthcare Costs
KINDNews
DIRECTION■ Unclear/unknown
SOURCES1
ENTITIES1
STORY SIZESTANDALONE
FIRST SEEN2026-10-06 11:30 UTC
LAST UPDATE2026-10-06 11:30 UTC
STATEactive
01 THE MACHINE READ
WHY IT MATTERS.
Independent cost-savings analysis supports digital-health value claims but is company-commissioned and small-scale.
Supports digital-health ROI narrative, unproven at scale
CATALYST TO WATCH
Payer contracts citing these savings
MAIN RISK
Commissioned study may not replicate broadly
FULL DISPATCH
A component study of the independent review by Aon found $5,077 in annual savings and 23.5% fewer inpatient discharges per Dario user with type 2 diabetes versus matched non-users Evaluation of 17 studies estimates $3.8 million to $10.8 million in annual savings for a 20,000-life...
02 THE STORY SO FAR
THE RECORD, IN ORDER.
STANDALONE ITEM — NOT YET FOLDED INTO A DEVELOPING STORY.
03 WHO'S INVOLVED
ENTITIES ON FILE.
CONTEXTHealthcare
04 RECEIPTS
THE SOURCE RECORD.
1 SOURCES CONFIRMED05 PROPAGATION
WHAT THIS TOUCHES.
→CORRELATIONshares Healthcare
Notre Dame researchers are developing AI technology to interpret nonverbal communication2026-10-06 12:02 UTC
Notre Dame researchers are developing AI technology to interpret nonverbal communication2026-10-06 12:02 UTC
→CORRELATIONshares Healthcare
Lycia seeks IPO for antibody degraders as TRexBio, Retension set terms2026-10-06 08:21 UTC
Lycia seeks IPO for antibody degraders as TRexBio, Retension set terms2026-10-06 08:21 UTC
→CORRELATIONshares Healthcare
New Peer-Reviewed Preclinical Study Demonstrates Regenerative Potential of Spinogenix's Tazbentetol for Treating Diabetic Retinal Neuropathy2026-10-06 12:30 UTC
New Peer-Reviewed Preclinical Study Demonstrates Regenerative Potential of Spinogenix's Tazbentetol for Treating Diabetic Retinal Neuropathy2026-10-06 12:30 UTC
→CORRELATIONshares Healthcare
Lupus Research Alliance Awards $3 Million to Transform How Lupus Treatment Response is Predicted and Personalized2026-10-06 12:32 UTC
Lupus Research Alliance Awards $3 Million to Transform How Lupus Treatment Response is Predicted and Personalized2026-10-06 12:32 UTC
←CORRELATIONshares Healthcare
Report of Possible $5 Billion Takeover Bid Sends Option Care Health Stock Higher2026-10-05 21:16 UTC
Report of Possible $5 Billion Takeover Bid Sends Option Care Health Stock Higher2026-10-05 21:16 UTC
←CORRELATIONshares Healthcare
Lundbeck presents Phase Ib data for Lu AF28996 in advanced Parkinson's disease, as Phase II trial begins2026-10-06 06:16 UTC
Lundbeck presents Phase Ib data for Lu AF28996 in advanced Parkinson's disease, as Phase II trial begins2026-10-06 06:16 UTC
KEEP READING THE MACHINE
Summaries are generated and may contain errors — every claim links its sources.